A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA

This is an interventional treatment trial for Hepatocellular Carcinoma focused on measuring Hepatocellular Carcinoma, Autologous Cytokine-Induced Killer Read More

Inclusion Criteria:

1. 20 to 80 years old men and women;
2. HCC diagnosed with typical imaging findings, or confirmed by needle liver biopsy;
3. Patients who are not a transplant candidate;
4. Patients who have no extrahepatic metastasis and are with measurable residual tumor after TACE, PEIT or RFA therapy;
5. Patients who have a life expectancy of at least 6 months;
6. Child-Pugh Class should be A or B;
7. Eastern Cooperative Oncology Group (ECOG) performance status score was 0-3;

8. Patients who have clinical laboratory test results as follows:

   • Absolute neutrophil count ≥ 1,500/µL or White blood cell ≥ 4,000/µL
   • Hemoglobin ≥ 8.5 g/dL
   • Platelet count ≥ 50,000/µL
   • Blood creatinine ≤ 1.5 x upper limit of normal
   • Total bilirubin < 3 x upper limit of normal
   • Albumin ≥ 2.8 g/dL
   • International normalized ratio (INR) / Partial thromboplastin time (PTT) < 1.5 x upper limit of normal
9. Written informed consent.

Exclusion Criteria:

1. Patients who have infiltrative or diffuse HCC;
2. Patients who have significant cardiovascular disease such as myocardial infarction occurred within recent 6 months, chronic heart failure or unstable coronary artery disease;
3. Patients who plan to receive systemic chemotherapy or target therapy;
4. Patients with other malignant tumor within the past 5 years before treatment;
5. Pregnant or lactating patients;
6. Patients with hemorrhage/bleeding event;
7. Patients with uncontrolled infections;
8. Known or suspected allergy to the investigational agent or any agent given in association with this trial;
9. Patients who have current Human Immunodeficiency Virus (HIV) or Treponema Pallidum (TP) infection;
10. Patients who are suffering from serious autoimmune disease;
11. Patients who have had long term use of or are using an immunosuppressant;
12. History of organ transplant;
13. Prior use of any anti-cancer treatments within 30 days or 5 half-lives (whichever is longer), except TACE, PEIT and RFA therapy;
14. Patients who have participated in another clinical study and received treatment within 30 days prior to the screening visit;
15. Mental conditions rendering the patient incapable of understanding the nature, scope, and consequences of the study;
16. Other situations that the researchers considered unsuitable for this study.